Allogene Therapeutics, Inc. Tenant Improvements
Allogene Therapeutics, Inc. (ALLO) had Tenant Improvements of $5.00 million as of 2023-12-31, per its 10-K filed 2024-03-14.
Financial Statements › Balance Sheet › Assets
us-gaap:TenantImprovements · last filed 2025-03-13
- 2023-12-31: Tenant Improvements $5.00M.
- 2023-09-30: Tenant Improvements $5.00M.
- 2023-06-30: Tenant Improvements $5.00M.
- 2023-03-31: Tenant Improvements $5.00M.
| Period end | Tenant Improvements |
|---|---|
| 2023-12-31 | $5.00M 10-K · filed 2024-03-14 |
| 2023-09-30 | $5.00M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $5.00M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $5.00M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $5.00M 10-K/A · filed 2024-03-14 |
| 2022-09-30 | $5.00M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $5.00M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $5.00M 10-Q · filed 2022-05-04 |
| 2021-09-30 | $5.00M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $5.00M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $5.00M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $5.00M 10-K · filed 2025-03-13 |
| 2020-09-30 | $5.00M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $5.00M 10-Q · filed 2020-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |